Origin Materials (ORGN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Board approved a plan of complete liquidation and dissolution, subject to stockholder approval, after evaluating strategic alternatives and concluding dissolution is in the best interests of stakeholders.
Workforce reduced by 59% in May 2026, discontinuing PET closures program and decreasing annual operating expenses by $14 million.
Management Incentive Plan established to align key employees with asset sale and wind-down process.
Financial highlights
Revenue for Q1 2026 was $0.5 million, down 91% from $5.4 million in Q1 2025, due to winding down of supply chain activation program.
Net loss for Q1 2026 was $17.7 million, a 33% improvement from $26.4 million in Q1 2025.
Cash, cash equivalents, and marketable securities totaled $32.6 million as of March 31, 2026.
Accumulated deficit reached $305.5 million as of March 31, 2026.
Net cash used in operating activities was $4.9 million for Q1 2026, compared to $8.4 million in Q1 2025.
Outlook and guidance
Substantial doubt exists about the ability to continue as a going concern due to insufficient liquidity and the planned dissolution.
If dissolution is approved, remaining assets will be liquidated and proceeds distributed to stockholders after settling liabilities.
Latest events from Origin Materials
- Stockholders will vote on a plan to dissolve the company and distribute $0.61–$3.54 per share.ORGN
Proxy filing15 May 2026 - Stockholders will vote on a proposed dissolution, with estimated payouts of $0.61–$3.48 per share.ORGN
Proxy filing14 May 2026 - Breakeven delayed to 2028 as PET cap commercialization progresses amid urgent liquidity needs.ORGN
Q4 202527 Mar 2026 - Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - $100M+ PET cap deal signed; Q2 loss $19.5M; Q4 2024 production on track.ORGN
Q2 20241 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026 - Key votes on reverse stock split and major share issuance set for February 2026.ORGN
Proxy Filing6 Jan 2026 - Approval sought for reverse split and convertible note share issuance to support listing and funding.ORGN
Proxy Filing6 Jan 2026